The rise in multiple-drug-resistant (MDR) phenotypes in Gram-negative pathogens is a major public health crisis. Pseudomonas aeruginosa is one of the leading causes of nosocomial infections in clinics. Treatment options for P. aeruginosa have become increasingly difficult due tdo its remarkable capacity to resist multiple antibiotics. The presence of intrinsic resistance factors and the ability to quickly adapt to antibiotic monotherapy warrant us to look for alternative strategies like combinatorial antibiotic therapy. Here, we report the frequency of P. aeruginosa multidrug-resistant and extensively drug-resistance (XDR) phenotypes in a super-specialty tertiary care hospital in north India. Approximately 60 percent of all isolated P. aeruginosa strains displayed the MDR phenotype. We found highest antibiotic resistance frequency in the emergency department (EMR), as 20 percent of isolates were resistant to 15 antipseudomonal antibiotics. Presence of plasmids with quinolone-resistance determinants were major drivers for resistance against fluoroquinolone. Additionally, we explored the possible combinatorial therapeutic options with four antipseudomonal antibiotics—colistin, ciprofloxacin, tobramycin, and meropenem. We uncovered an association between different antibiotic interactions. Our data show that the combination of colistin and ciprofloxacin could be an effective combinatorial regimen to treat infections caused by MDR and XDR P. aeruginosa.
The aim of this chapter was to investigate the genetic diversity of the T7SS across Staphylococcus aureus strains and its role in virulence and interbacterial competition. The ess locus is responsible for encoding the type VII protein secretion system (T7SS) in Staphylococcus aureus. A crucial player within this system is EssC, a membrane-bound ATPase with multiple domains crucial for substrate identification and protein transport via the T7SS. Moreover, it plays a pivotal role in intraspecies competition by secreting toxins capable of depolarising membranes and nucleases, thereby inhibiting the growth of strains lacking neutralising immunity proteins. The findings from the genomic analysis revealed that the T7SS is situated within genomic clusters housing an array of toxin and immunity genes, indicating robust conservation of this system among staphylococci species. Notably, in species like Staphylococcus warneri, where the T7SS is absent, there are genomic islands harbouring diverse immune protein-encoding genes. This observation underscores the pivotal role of the secretion system in mediating bacterial antagonistic interactions within microbial communities. The T7SS is a crucial system for Staphylococcus aureus, contributing to its virulence and enabling it to outcompete with other strains through the secretion of toxins and nucleases.
25 November 2025 in Indian Journal of Microbiology
Despite significant therapeutic advances, T2DM remains a global public health challenge that leads to multiple complications, including cardiovascular, renal, hepatic, and neurodegenerative disorders. Mitochondrial dysfunction and impaired mitophagy remain fundamental, yet incompletely understood, mechanisms driving pancreatic β-cell failure, chronic inflammation, insulin resistance and diabetic complications. Emerging evidence indicates that noncoding RNAs (including microRNAs, long noncoding RNAs, and circular RNAs) are critical regulators of mitophagy and mitochondrial quality control mechanisms across metabolically active tissues. This review comprehensively examines the interplay between mitochondrial dysfunction, mitophagy impairment, and T2DM pathophysiology. It provides an overview of recent mechanistic insights into mitophagy–noncoding RNA interactions in T2DM, emphasizing tissue-specific effects, and highlights the translational potential of mitophagy-associated proteins and regulatory ncRNAs as diagnostic biomarkers and therapeutic targets. By bridging fundamental molecular biology with translational and clinical perspectives, further it provides a comprehensive framework to guide future research, accelerate biomarker discovery, and support the development of personalized interventions aimed at reducing the growing worldwide burden of T2DM and its complications.